Year: 2017
Type: review
Abstract: There are many factors that can influence the pharmacokinetics (PK) of a mAb or Fc-fusion molecule with the primary determinant being FcRn-mediated recycling. Through Fab or Fc engineering, IgG-FcRn interaction can be used to generate a variety of therapeutic antibodies with significantly enhanced half-life or ability to remove unwanted antigen from circulation. Glycosylation of a mAb or Fc-fusion protein can have a significant impact on the PK of these molecules. mAb charge can be important and variants with pI values of 1-2 unit difference are likely to impact PK with lower pI values being favorable for a longer half-life. Most mAbs display target mediated drug disposition (TMDD), which can have significant consequences on the study designs of preclinical and clinical studies. The PK of mAb can also be influenced by anti-drug antibody (ADA) response and off-target binding, which require careful consideration during the discovery stage. mAbs are primarily absorbed through the lymphatics via convection and can be conveniently administered by the subcutaneous (sc) route in large doses/volumes with co-formulation of hyaluronidase. The human PK of a mAb can be reasonably estimated using cynomolgus monkey data and allometric scaling methods.
Source: Protein & Cell
Author: Liming Liu
Institution: United States Military Academy
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: monoclonal antibodies, Fc fusion protein, pharmacokinetics, antibody half-life, glycosylation, isoelectric point, target-mediated drug disposition, anti-drug antibodies, off-target binding, lymphatic absorption, subcutaneous administration, hyaluronidase, Macaca fascicularis, allometric scaling
Open Access status: gold
Estimated APC paid: $2,700
OpenAlex ID: W2606721249
